Table 1.
Melanoma trials: published data
| Published Trials | Therapy | Phase | Patient (n) | PR% | medPFS (months) | TTP (months) | mOS (months) | Year | Ref |
|---|---|---|---|---|---|---|---|---|---|
| Varker et al. | Bevacizumab ± interferon- α2b | (II) | 32 | 6 0 | 3.0 3.0 | 10 8.5 | 2007 | [89] | |
| Von Moos et al. | Temozolomide, bevacizumab | (II) | 62 | 15 | 4.2 | 9.6 | 2011 | [96] | |
| Grignol et al. | Bevacizumab, high dose interferon α-2b | (II) | 25 | 25 | 4.8 | 17 | 2011 | [90] | |
| Egberts et al. | Pegylated interferon- α2b, sorafenib | (II) | 55 | 3.6 | 2.5 | 9.6 | 2011 | [123] | |
| Carvajal et al. | Imatininib | (II) | 28 | 21 | 3.0 | 11 | 2011 | [114] | |
| Hainsworth et al. | Bevacizumab, everolimus | (II) | 57 | 12 | 4.0 | 8.6 | 2010 | [124] | |
| Del Vechio et al. | Fotemustine, bevacizumab | (II) | 20 | 15 | 8.3 | 20.5 | 2010 | [94] | |
| Vihinen et al. | Bevacizumab, dacarbazine, IFN-α2a | (II) | 26 | 15 | 2.3, 8.1 responders | 11.5 | 2010 | [91] | |
| Ott el al. | Sorafenib | (II) | 36 | 3 | 2.0 | 2010 | [102] | ||
| Hodi, O'Day et al. | Ipilimumab ± gp100 vaccine | (III) | 676 | 9.5 5.5 | 2.86 2.76 | 10.0 6.4 | 2010 | [125] |
PR - Partial Response, medPFS – median Progression Free Survival, TTP - Time to Progression, mOS – median Overall Survival